Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

Minard-Colin, 2015, Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead, J Clin Oncol, 33, 2963, 10.1200/JCO.2014.59.5827 Crump, 2014, Season of birth and risk of Hodgkin and non-Hodgkin lymphoma, Int J Cancer, 135, 2735, 10.1002/ijc.28909 Bornkamm, 2009, Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers, Int J Cancer, 124, 1745, 10.1002/ijc.24223 Vaillant, 2019, Seroepidemiological analysis and literature review of the prevalence of Epstein-Barr virus and herpesvirus infections in pediatric cases with non-Hodgkin lymphoma in Central Europe, Pediatr Blood Cancer, 66, 10.1002/pbc.27752 Malcolm, 2016, Challenging perspectives on the cellular origins of lymphoma, Open Biol, 6, 10.1098/rsob.160232 Attarbaschi, 2016, Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents, Haematologica, 101, 1581, 10.3324/haematol.2016.147116 Morris, 1994, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma, Science, 263, 1281, 10.1126/science.8122112 Dalla-Favera, 1987, Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis, Ann N Y Acad Sci, 511, 207, 10.1111/j.1749-6632.1987.tb36249.x Malcolm, 2016, Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress, Nat Commun, 7, 10.1038/ncomms10087 Murphy, 1980, Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults, Semin Oncol, 7, 332 Rosolen, 2015, Revised international pediatric Non-Hodgkin lymphoma staging system, J Clin Oncol, 33, 2112, 10.1200/JCO.2014.59.7203 2019, Abstracts from the 51st Congress of the International Society of Paediatric Oncology (SIOP) Lyon, France, October 23–26, 2019, Pediatr Blood Cancer, 66 Sandlund, 2015, International pediatric Non-Hodgkin lymphoma response criteria, J Clin Oncol, 33, 2106, 10.1200/JCO.2014.59.0745 Bogaerts, 2015, Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative, Eur J Cancer, 51, 271, 10.1016/j.ejca.2014.10.027 Woessmann, 2005, The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95, Blood, 105, 948, 10.1182/blood-2004-03-0973 Minard-Colin, 2020, Rituximab for high-risk, mature B-cell non-Hodgkin's ymphoma in children, N Engl J Med, 382, 2207, 10.1056/NEJMoa1915315 Meinhardt, 2010, Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia, J Clin Oncol, 28, 3115, 10.1200/JCO.2009.26.6791 Burke, 2021, Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: a multicenter phase II trial, J Clin Oncol, 39, 3716, 10.1200/JCO.21.00920 Brugières, 2009, Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group, J Clin Oncol, 27, 897, 10.1200/JCO.2008.18.1487 Landmann, 2017, Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma, Haematologica, 102, 2086, 10.3324/haematol.2015.139162 Le Deley, 2010, Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial, J Clin Oncol, 28, 3987, 10.1200/JCO.2010.28.5999 Mussolin, 2020, Prognostic factors in childhood anaplastic large cell lymphoma: long term results of the international ALCL99 trial, Cancers (Basel), 12, 10.3390/cancers12102747 Attarbaschi, 2020, Rare non-Hodgkin lymphoma of childhood and adolescence: a consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma, Pediatr Blood Cancer, 67, 10.1002/pbc.28416 Woessmann, 2020, Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy, Blood, 135, 1124 Burkhardt, 2021, Treatment and outcome analysis of 639 relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations, Cancers (Basel), 13, 10.3390/cancers13092075 Knörr, 2020, Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the international, prospective ALCL-relapse trial, J Clin Oncol, 38, 3999, 10.1200/JCO.20.00157 Ehrhardt, 2019, Late health outcomes after contemporary Lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the childhood cancer survivor study, J Clin Oncol, 37, 2556, 10.1200/JCO.19.00525 Knörr, 2021, Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma, Haematologica, 106, 3232, 10.3324/haematol.2021.278971 Dourthe, 2022, Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study, Haematologica, 107, 2173, 10.3324/haematol.2021.280257 Dave, 2006, Molecular diagnosis of Burkitt's lymphoma, N Engl J Med, 354, 2431, 10.1056/NEJMoa055759 Hummel, 2006, A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling, N Engl J Med, 354, 2419, 10.1056/NEJMoa055351 Masqué-Soler, 2015, Clinical and pathological features of Burkitt lymphoma showing expression of BCL2—an analysis including gene expression in formalin-fixed paraffin-embedded tissue, Br J Haematol, 171, 501, 10.1111/bjh.13624 Wienand, 2021, Molecular classification of aggressive lymphomas-past, present, future, Hematol Oncol, 39, 24, 10.1002/hon.2847 Szczepanowski, 2017, Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents, Br J Haematol, 179, 116, 10.1111/bjh.14812 Klapper, 2008, Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials, Blood, 112, 1374, 10.1182/blood-2008-01-136465 Paul, 2018, Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC, Leuk Lymphoma, 59, 1213, 10.1080/10428194.2017.1365851 Schmitz, 2018, Genetics and pathogenesis of diffuse large B-cell lymphoma, N Engl J Med, 378, 1396, 10.1056/NEJMoa1801445 Chapuy, 2018, Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nat Med, 24, 679, 10.1038/s41591-018-0016-8 Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 202; 36: 1720–48. Campo, 2022, The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee, Blood, 140, 1229, 10.1182/blood.2022015851 Mussolin, 2003, Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt's lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32), Leukemia, 17, 585, 10.1038/sj.leu.2402828 Lovisa, 2009, IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis, Lab Invest, 89, 1182, 10.1038/labinvest.2009.81 Burkhardt, 2022, Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age, Nat Commun, 13, 10.1038/s41467-022-31355-8 Newman, 2022, Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma, Leukemia, 36, 781, 10.1038/s41375-021-01444-6 Callens, 2012, Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma, J Clin Oncol, 30, 1966, 10.1200/JCO.2011.39.7661 Khanam, 2021, Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance, Blood, 137, 2347, 10.1182/blood.2020005381 Damm-Welk, 2015, Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK, Front Biosci (Schol Ed), 7, 205, 10.2741/s434 Quelen, 2021, Minimal residual disease monitoring using a 3′ALK universal probe assay in ALK-positive anaplastic large-cell lymphoma: ddPCR, an attractive alternative method to real-time quantitative PCR, J Mol Diagn, 23, 131, 10.1016/j.jmoldx.2020.11.002 Lovisa, 2020, RNY4 in circulating exosomes of patients with pediatric anaplastic large cell lymphoma: an active player?, Front Oncol, 10, 238, 10.3389/fonc.2020.00238 Mussolin, 2007, Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood, J Clin Oncol, 25, 5254, 10.1200/JCO.2007.11.3159 Richter, 2012, Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing, Nat Genet, 44, 1316, 10.1038/ng.2469 Rohde, 2017, Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols, Haematologica, 102, 1091, 10.3324/haematol.2016.156885 Ramis-Zaldivar, 2020, Distinct molecular profile of IRF4-rearranged large B-cell lymphoma, Blood, 135, 274, 10.1182/blood.2019002699 Reutter, 2021, Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma, Leukemia, 35, 639, 10.1038/s41375-020-0862-5 Forde, 2021, Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy, Br J Haematol, 192, 354, 10.1111/bjh.17043 Pearson, 2019, ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children, Eur J Cancer, 110, 74, 10.1016/j.ejca.2019.01.013 Burkhardt, 2019, Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities, Br J Haematol, 185, 1158, 10.1111/bjh.15793 Hayashi, 2020, Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children's Oncology Group AALL0434, J Clin Oncol, 38, 3062, 10.1200/JCO.20.00531 Trinquand, 2021, Toward pediatric T lymphoblastic lymphoma stratification based on minimal disseminated disease and NOTCH1/FBXW7 status, HemaSphere, 5, e641, 10.1097/HS9.0000000000000641 Béné, 2011, Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10, Leukemia, 25, 567, 10.1038/leu.2010.312 Dworzak, 2018, AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia, Cytometry B Clin Cytom, 94, 82, 10.1002/cyto.b.21518 Oschlies, 2011, Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel, Am J Surg Pathol, 35, 836, 10.1097/PAS.0b013e318213e90e Wrobel, 2011, Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial, Pediatr Blood Cancer, 56, 1071, 10.1002/pbc.22940 Woessmann, 2011, Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study, J Clin Oncol, 29, 3065, 10.1200/JCO.2011.34.8417 Brugières, 2000, Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology, Ann Oncol, 11, 53, 10.1023/A:1008352726155 Mori, 2006, Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan, Br J Haematol, 132, 594, 10.1111/j.1365-2141.2005.05910.x Lamant, 2011, Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study, J Clin Oncol, 29, 4669, 10.1200/JCO.2011.36.5411 Mussolin, 2021, Minimal disease monitoring in pediatric non-Hodgkin's lymphoma: current clinical application and future challenges, Cancers (Basel), 13, 10.3390/cancers13081907 Locatelli, 2018, Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study, Lancet Haematol, 5, e450, 10.1016/S2352-3026(18)30153-4 Mossé, 2017, Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study, J Clin Oncol, 35, 3215, 10.1200/JCO.2017.73.4830 Mellgren, 2016, Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases, Ann Hematol, 95, 1295, 10.1007/s00277-016-2722-y Ronceray, 2018, Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection, Pediatr Blood Cancer, 65, 10.1002/pbc.26932 Bomken, 2018, Current understanding and future research priorities in malignancy associated with inborn errors of immunity and DNA repair disorders: the perspective of an interdisciplinary working group, Front Immunol, 9, 10.3389/fimmu.2018.02912 Attarbaschi, 2019, Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents, Blood Adv, 3, 4291, 10.1182/bloodadvances.2019001062